LXEO · XBRL financial data
Lexeo Therapeutics financial statements, every fiscal year
The same tables from 3 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (LXEO's year ends in late December)
| In thousands of dollars | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|
| Research and development | 53,130 | 74,091 | 63,797 |
| General and administrative | 15,383 | 31,675 | 45,460 |
| Total operating expenses | 68,513 | 105,766 | 109,257 |
| Operating income (loss) | (68,513) | (105,766) | (109,257) |
| Interest income | 2,867 | 7,556 | 6,130 |
| Interest expense | 205 | 137 | 95 |
| Other income (expense) | (13) | (9) | (18) |
| Income tax expense (benefit) | — | 0 | 0 |
| Net income (loss) | (66,394) | (98,333) | (99,961) |
| Earnings per share, basic USD per share | (12.40) | (3.09) | (1.86) |
| Earnings per share, diluted USD per share | (12.40) | (3.09) | (1.86) |
| Weighted average shares, basic thousands of shares | 5,354 | 31,787 | 53,645 |
| Weighted average shares, diluted thousands of shares | 5,354 | 31,787 | 53,645 |
Balance sheet
CSVFiscal years (LXEO's year ends in late December)
| In thousands of dollars | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|
| Cash and cash equivalents | 121,466 | 35,014 | 63,000 |
| Short-term investments | — | 86,504 | — |
| Marketable securities | — | 86,504 | 118,767 |
| Marketable securities, non-current | — | 7,012 | 64,801 |
| Prepaid and other current assets | 2,828 | 4,603 | 6,625 |
| Total current assets | 124,294 | 126,121 | 188,392 |
| Property and equipment, net | 1,056 | 1,028 | 1,139 |
| Right-of-use asset | 9,442 | 8,069 | 6,578 |
| Total assets | 139,807 | 146,942 | 268,688 |
| Accounts payable | 3,794 | 6,417 | 4,856 |
| Total current liabilities | 17,239 | 22,846 | 16,808 |
| Lease liability, non-current | 7,786 | 6,437 | 4,884 |
| Total liabilities | 26,272 | 30,100 | 22,019 |
| Accumulated deficit | (181,840) | (280,173) | (380,134) |
| Total stockholders' equity | 113,535 | 116,842 | 246,669 |
| Total liabilities and equity | 139,807 | 146,942 | 268,688 |
| Common shares outstanding (cover page) thousands of shares | 26,669 | 33,197 | 74,087 |
Cash flows
CSVFiscal years (LXEO's year ends in late December)
| In thousands of dollars | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|
| Net income (loss) | (66,394) | (98,333) | (99,961) |
| Stock-based compensation | 3,043 | 12,474 | 12,132 |
| Net cash from operating activities | (59,496) | (81,151) | (98,561) |
| Purchases of property and equipment | 115 | 481 | 397 |
| Net cash from investing activities | (165) | (94,077) | (90,252) |
| Proceeds from issuing common stock | — | — | 270 |
| Net cash from financing activities | 103,791 | 88,776 | 216,795 |
| Net change in cash | 44,130 | (86,452) | 27,982 |
Compare with peers
SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Lexeo Therapeutics | 92,834 | not reported | (17,597)* | 82.0M | 13.3 quarters | 10-QJun 30, 2026 |
| SELLAS Life Sciences Group | 138,343 | not reported | (7,588)* | 201.9M | 18.2 quarters | 10-QJun 30, 2026 |
| Precigen | 14,959 | 74,148 | 11,883* | 358.5M | — | 10-QSep 30, 2026 |
| Perspective Therapeutics | 48,488 | not reported | (20,650)* | 114.2M | 11.5 quarters | 10-QJun 30, 2026 |
| Rocket Pharmaceuticals | 224,507 | 0 | (39,613)* | 109.8M | 7.2 quarters | 10-QJun 30, 2026 |
| Natures Sunshine Products | 89,377 | 116,603 | 10,750* | 17.3M | — | 10-QSep 30, 2026 |
| Lifecore Biomedical | 23,035 | 25,322 | 6,946* | 37.9M | — | 10-QSep 30, 2026 |
| Tvardi Therapeutics | 15,765 | not reported | (9,228)* | 13.3M | 1.7 quarters | 10-QJun 30, 2026 |
| Silence Therapeutics | 72,054 | 0 | 1,518* | 141.7M | — | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.
Data on this page was fetched . The filing on SEC.gov is the record.